Screener
Stoke Therapeutics, Inc. STOK EPS (Basic)
EPS (Basic) at other companies
Other financials
Where this comes from
Reported directly by Stoke Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.
The source filing: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211874
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Provision for income taxes | — | 1,278 |
| Net (loss) income | $(50,003) | $112,879 |
| Net (loss) income per share: | ||
| Basic | $(0.79) | $1.95 |
| Diluted | (0.79) | 1.90 |
| Weighted-average common shares outstanding: | ||
| Basic | 63,063,507 | 57,862,674 |
| Diluted | 63,063,507 | 59,398,600 |
Item 1. Financial Statements.
FAQ
- What is Stoke Therapeutics, Inc.'s EPS (basic)?
- Stoke Therapeutics, Inc. (STOK) reported EPS (basic) of -$0.79 in Q1 2026.
- How has Stoke Therapeutics, Inc.'s EPS (basic) changed year-over-year?
- Stoke Therapeutics, Inc.'s EPS (basic) decreased by 140.5% year-over-year, from $1.95 to -$0.79.
- What is the long-term trend for Stoke Therapeutics, Inc.'s EPS (basic)?
- Over 4 years (2021 to 2025), Stoke Therapeutics, Inc.'s EPS (basic) has grown at a -54.5% compound annual growth rate (CAGR), from -$2.34 to -$0.10.
- What does EPS (basic) mean?
- Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.
Ask your AI about Stoke Therapeutics, Inc.'s eps (basic).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude